SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-034747
Filing Date
2022-03-17
Accepted
2022-03-17 07:17:01
Documents
13
Period of Report
2022-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm229353d1_8k.htm   iXBRL 8-K 26051
2 EXHIBIT 99.1 tm229353d1_ex99-1.htm EX-99.1 55323
  Complete submission text file 0001104659-22-034747.txt   262737

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acxp-20220317.xsd EX-101.SCH 3042
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acxp-20220317_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acxp-20220317_pre.xml EX-101.PRE 22601
7 EXTRACTED XBRL INSTANCE DOCUMENT tm229353d1_8k_htm.xml XML 3607
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40536 | Film No.: 22746716
SIC: 2834 Pharmaceutical Preparations